| Trial ID: | L0841 |
| Source ID: | NCT04614142
|
| Associated Drug: |
Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]
|
| Title: |
Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis Access
|
| Acronym: |
|
| Status: |
WITHDRAWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
End Stage Renal Disease|Chronic Hepatitis c
|
| Interventions: |
DRUG: Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]
|
| Outcome Measures: |
Primary: Hepatitis C viral load (RNA), Negative hepatitis C viral load (RNA) tested using PCR at 12 weeks post-treatment (SVR12), 20 weeks post-transplant (12-weeks post-treatment) |
|
| Sponsor/Collaborators: |
Sponsor: Massachusetts General Hospital
|
| Gender: |
FEMALE
|
| Age: |
ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
0
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION
|
| Start Date: |
2020-11-13
|
| Completion Date: |
2021-08-04
|
| Results First Posted: |
|
| Last Update Posted: |
2022-03-08
|
| Locations: |
Massachusetts General Hospital, Boston, Massachusetts, 02114, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT04614142
|
